PHAT Analyst Ratings
Phathom Pharmaceuticals, Inc. (PHAT) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $566.3M, listed on NASDAQ, employing roughly 371 people, carrying a beta of 0.50 to the broader market. Phathom Pharmaceuticals, Inc. Led by Steven L. Basta, public since 2019-10-25.
Analyst Ratings
In the October 2026 monthly count, 12 analysts rated PHAT: 2 Strong Buy, 8 Buy, 2 Hold, 0 Sell and 0 Strong Sell.
Twelve months earlier, in October 2025: 10 analysts, 2 Strong Buy, 7 Buy, 1 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $17.33
- Median Target
- $18.00
- High
- $22.00
- Low
- $10.00
- Targets Published, Last 12 Months
- 13
Recent Price Targets
The 5 most recent of 13 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Oct 14, 2026 | Jefferies | Glen Santangelo | $16.00 | $7.00 |
| Sep 9, 2026 | Leerink Partners | Not named | $10.00 | $9.43 |
| Aug 14, 2026 | Barclays | Not named | $14.00 | $9.58 |
| Jul 31, 2026 | Craig-Hallum | Chase Knickerbocker | $20.00 | $9.32 |
| Jul 31, 2026 | Guggenheim | Not named | $22.00 | $9.03 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 2026 | Barclays | maintain | Overweight | Overweight |
| Jul 31, 2026 | Guggenheim | maintain | Buy | Buy |
| Jul 31, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 30, 2026 | Needham | maintain | Buy | Buy |
| Jun 17, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
Quantitative Rating
PHAT carries a model grade of C (overall score 2 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read PHAT Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked PHAT analyst ratings questions
- What is the PHAT consensus price target?
- As of the latest aggregator update, Phathom Pharmaceuticals, Inc. (PHAT) carries a consensus 12-month price target of $17.33. Target ranges run from a low of $10.00 to a high of $22.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on PHAT?
- In the October 2026 monthly count, 12 analysts rated PHAT, and the distribution tilts to the Buy side: 2 Strong Buy, 8 Buy, 2 Hold, 0 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has PHAT seen?
- The five most recent ratings actions on PHAT appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect PHAT options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.